Vanadium and cancer treatment: Antitumoral mechanisms of three oxidovanadium(IV) complexes on a human osteosarcoma cell line

Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium—Synthesis, structure and bioactivity of the vanadium complex

“…On the whole, at the current stage of research the mechanism of action still remains obscure and necessitates further investigations. Delivery of vanadium by application of vanadyl complexes for the treatment of cancer has been pursued preclinically in various ways (including, e.g., oxodiacetate derivatives [50] or phenanthrolines [51] as ligands), but the use of an aminopolycarboxylate ligand reported here is unlike previous efforts. …”

“…IC50 values were obtained by fitting the concentration-dependent inhibition curves using the Four Parameter model. The complex showed a marked inhibitory activity against protein tyrosine phosphatase 1B, with a moderate value of IC 50 = 95±1 μM as compared with vanadate, which inhibits a wide variety of PTPs with an IC 50 in the low μM region [52].…”

Physiological roles of peroxido-vanadium complexes: Leitmotif as their signal transduction pathway

“…Although the use of vanadium in cancer therapeutics is not the focus of this review, many trials have been completed [32] and a few vanadium complexes have been developed for cancer therapies [33][34][35][36][37].…”

Vanadium pentoxide increased PTEN and decreased SHP1 expression in NK-92MI cells, affecting PI3K-AKT-mTOR and Ras-MAPK pathways

“…Mice and humans exposed to pollutants derived from burning coal or diesel exhaust particles show a diminished NK cell function (Hurd and Whalen 2011;Dutta et al 2012;Wortham et al 2012;Muller et al 2013). Interleukin (IL)-2, a cytokine required for NK cell proliferation and activation (Suzuki et al 1983;Bi et al 2014;Leon et al 2014) has its effects mediated through IL-2 receptors and subsequently janus kinase/signal transducers and activators of transcription (JAK/STAT), phosphoinositide 3-kinase-protein kinase B-mechanistic target of Rapamycin (PI3K-Akt-mTOR) and mitogen-activated protein kinase (MAPK) signaling pathways (Lu et al 1998;Liao et al 2013). Impairment of the IL-2/IL-2 receptor signaling pathway suppresses immune cell proliferation and other functions (Wu et al 2009).…”